We read with great interest the report by Viviani Anselmi et al. (1) on the predictability of platelet reactivity as compared with gene polymorphism in patients undergoing elective percutaneous coronary intervention (PCI). The authors conclude that CYP2C19 metabolizer status independently predicts major adverse cardiac events, whereas platelet reactivity is only an independent predictor in high-risk patients.
Reply

Platelet Reactivity Is Preferred Over Genotyping in Monitoring Efficacy of Antiplatelet Therapy
We thank Drs. Breet and ten Berg for their interest in our paper (1) . When we designed our study, we aimed to confirm and expand previous observations demonstrating the clinical usefulness of clopidogrel-pathway genotyping and on-treatment platelet residual (OTR) testing in predicting major adverse cardiac events (MACE) in patients with stable coronary artery disease (CAD) receiving drug-eluting stents (DES) and under dual antiplatelet (clopidogrel plus aspirin) therapy. Our results confirmed that CYP2C19 metabolizer status is an independent predictor of MACE after DES implantation and can be used for prognostication in all stable CAD patients. In contrast, high OTR, as assessed with the We would like to stress the following issues:
1. The majority of previous positive studies included patients with acute coronary syndromes, whereas our target population included only patients with stable CAD. When dealing with stable CAD patients, with an expected overall low MACE rate, the assessment of OTR is unlikely to have any prognostic value due to modest sensitivity and specificity. On the contrary, when dealing with a high-risk population (including stable patients with DM and/or CKD and patients with acute coronary syndrome), OTR assessment may have a relevant clinical benefit (2-6). This may explain why, for example, in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents) trial, the OTR (assessed with the VerifyNow P2Y 12 test) was a strong independent predictor of stent thrombosis at 30 days only in patients with acute coronary syndromes, but not in patients with stable CAD (7).
This result has been also confirmed by Park et al. (8). 2. The POPULAR (Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients
Undergoing Elective PCI) trial demonstrated a modest accuracy of 4 platelet reactivity tests (including the VerifyNow P2Y 12 Test) in predicting clinical outcome (9) . Possible explanations for the discrepancy between our study and the POPULAR trial are: differences in the risk at baseline of the patient populations (as suggested by the different rates of DM, CKD, and bifurcation lesions) and differences in the type of stent implanted in the 2 studies. Indeed, in our study, the extensive use of second-generation DES may have had a relevant role in reducing the MACE rate at follow-up (10 Please note: Dr. Condorelli has received research grants from the National Research Council of Italy and the Italian Ministry of Health (Progetto "Apice"). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
